Weight-loss injections, renowned for aiding significant weight loss, may offer a lifeline to patients with advanced cancer that has metastasized to the brain, according to a new study. These drugs, known as GLP-1 receptor agonists, include Wegovy and Ozempic. Initially developed to manage type 2 diabetes, these medications have gained global attention for their weight-loss benefits.
The study does not claim these injections directly treat cancer. Instead, it suggests a potentially crucial role: they might extend the lives of severely ill patients. The research centers on brain metastases, a condition where cancer cells migrate from other parts of the body, such as the lungs, breasts, or skin, to form tumors in the brain. Sadly, brain metastases are common and often signal a late, perilous stage of cancer.
When Diabetes Drugs Meet Cancer Care
Many patients with brain metastases also suffer from type 2 diabetes, a condition that complicates the management of serious illnesses. High blood sugar can lead to chronic inflammation, damage blood vessels, and weaken the body’s resilience. In clinical practice, steroids are prescribed to alleviate symptoms like brain swelling, but they can exacerbate diabetes by raising blood sugar levels. This has prompted researchers to explore whether GLP-1 drugs might offer additional benefits.
Laboratory studies suggest these drugs may protect brain cells, reduce inflammation, and preserve the brain’s blood supply. However, evidence from real-world clinical practice has been scarce until now. The new study, published in JAMA Network Open, sought to address this gap.
Researchers used a medical database of anonymized health records from 151 hospitals worldwide, examining patients with cancer, type 2 diabetes, and brain metastases between 2018 and 2024.
The researchers focused on whether these patients had been prescribed a GLP-1 drug, such as semaglutide, dulaglutide, liraglutide, or tirzepatide, around the time of their diabetes and brain metastases diagnoses. To ensure a fair comparison, they matched patients who received these injections with similar patients who did not, considering factors like age, sex, type of cancer, and other medical conditions.
Key Findings and Implications
The study identified over 19,000 patients with cancer, brain metastases, and type 2 diabetes. Among them, 866 were treated with a GLP-1 drug, while more than 11,000 were not. After careful matching, the analysis compared two balanced groups of 850 patients each, similar in terms of their cancers, body mass index, diabetes control, and other health issues.
The researchers discovered that patients taking GLP-1 drugs were 37% less likely to die during the three-year follow-up period than those who were not.
This pattern was consistent across several major cancer types, including lung cancer, breast cancer, and melanoma, and appeared across different drugs within the GLP-1 class. When compared with other modern diabetes treatments, such as SGLT2 inhibitors and DPP-4 inhibitors, the GLP-1 group showed better outcomes, suggesting that GLP-1 signaling itself might be beneficial.
Limitations and Future Directions
Despite these promising findings, the researchers emphasize a significant limitation: the study relied on retrospective medical records rather than controlled trials. To establish a definitive link, randomized clinical trials are necessary, where patients are deliberately assigned to receive a GLP-1 drug or another treatment and then monitored over time.
So, how might these “weight-loss jabs” aid patients with brain metastases? One possibility is indirect: by improving diabetes management, better blood sugar control, reduced body weight, and improved heart health could help patients better tolerate surgery, radiotherapy, or chemotherapy.
Direct effects on the brain are also plausible. GLP-1 receptors, present in brain tissue, play a role in controlling inflammation, protecting nerve cells, and maintaining the blood-brain barrier. Animal studies suggest that activating these receptors can reduce brain cell damage and enhance their function, potentially helping the brain tolerate metastatic tumors better or making it a less hospitable environment for cancer cells.
Conclusion and Next Steps
For patients and families, it’s crucial to understand what this research implies. The study does not advocate for people with brain metastases to immediately start GLP-1 drugs, nor do these medications replace standard cancer treatments like radiotherapy, surgery, targeted therapies, or immunotherapy.
The potential benefits were observed specifically in individuals with type 2 diabetes. Like any medication, GLP-1 injections can cause side effects such as nausea and vomiting, and there are ongoing discussions about rare but serious risks. Anyone considering these drugs should seek guidance from both oncology and diabetes specialists rather than making decisions based on a single study.
Nonetheless, the findings open an intriguing research avenue linking cancer, metabolism, and brain health. If future trials confirm that GLP-1 drugs genuinely improve survival in patients with brain metastases and diabetes, they could eventually become part of supportive care for those facing this challenging complication.
Courtesy of The Conversation. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style, and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).
